Navigation Links
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Date:7/2/2009

ltaq(R) for patients in a therapeutic area that has seen few new treatment options in the last twenty years," said Marc Cluzel, MD, Senior Vice President, Research and Development, sanofi-aventis. "Sanofi-aventis' commitment to research and development in this area is rewarded today, and we hope it will benefit many patients suffering from this disease."

The incidence of atrial fibrillation is growing worldwide in relation to aging populations. It is emerging as a public health concern and affects about 2.5 million people in the United States and 4.5 million people in the European Union. Atrial fibrillation is a potentially life-threatening condition, with significant burden on patients, health care providers and payers.

"It is exciting that Multaq(R) will now be available as a treatment option for patients with paroxysmal or persistent atrial fibrillation or atrial flutter," said Stuart Connolly, M.D., Professor of Medicine & Director, Division of Cardiology, McMaster University, Hamilton, Canada, and co-principal investigator in the ATHENA study. "Based on clinical studies, Multaq(R) reduces the risk of cardiovascular hospitalizations in patients with atrial fibrillation / atrial flutter, this outcome could change the way we approach the management of the disease."

Multaq(R) is to be given twice daily as a 400 mg tablet and should be taken as one tablet with the morning and evening meals. Treatment with Multaq(R) can be initiated in an outpatient setting. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash.

A registration dossier of Multaq(R) is also under regulatory review by the European Medicines Agency (EMEA).

About dronedarone (Multaq(R))

Multaq(R), discovered and developed by sanofi-aventis, is one of the major therapeutic i
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
2. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
3. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
4. ClearWay Minnesota(SM) Board Approves Four Regional Grants
5. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
6. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
7. Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
8. FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
9. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
10. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
11. FDA Approves Plan B Pill for 17-Year-Olds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Offers Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging at an ... ... Los Angeles, CA (PRWEB) December 16, 2009 -- Actively healthy ... in all natural skin care for their children as ... children featuring the beloved artwork of The Very Hungry Caterpillar ...
(Date:12/16/2009)... direct link has been found, , , WEDNESDAY, Dec. 16 ... commonly linked to food poisoning and the stomach pain ... cause of some urinary tract infections. , Researchers have ... from stores and restaurants and in women with the ... were transmitted directly to the women through the food ...
(Date:12/16/2009)... promote Massachusetts companies through annual marketing campaign , ... ... BioSpace unveiled the 2010 Genetown™ Hotbed Campaign as ... , ,Genetown is sponsored by MassBio and showcases ... The campaign places each entity’s brand on an electronic ...
(Date:12/16/2009)... government report shows, , , WEDNESDAY, Dec. 16 (HealthDay News) ... reached almost 78 years, a record high, federal health ... can expect to live to 80.4 years on average ... from the U.S. Centers for Disease Control and Prevention. ... live longer than their parents, life expectancy in the ...
(Date:12/16/2009)... Dec. 16 Medical travel facilitator Companion ... in Puerto Rico into its network of international ... lower than those at mainland U.S. facilities. ,, ... medical travel assistance and preferred pricing for its ... treatment at either HIMA San Pablo Bayamon or ...
Breaking Medicine News(10 mins):Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:Thriving Bioscience Region Leaves Its Mark 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2
... Ill., Feb. 25 Omron Healthcare, Inc. ... chief operating officer. With,an extensive background in ... sales and profit growth in their mainstay ... and professional medical. Kondraske,s experience as a ...
... CHARLOTTESVILLE, Va., Feb. 25 Meddius, an ... will,provide integration technology and professional services to ... control system,which provides hospitals with a Web-based, ... healthcare associated infections (HAIs). The announcement,was made ...
... chain management system enhanced to support multifaceted hospital, environments; ... ... ORLANDO, Fla., Feb. 25 HIMSS ,08 -- ... system solutions to acute,healthcare facilities, today introduced its OptiFlex(TM) ...
... Platform helps hospitals automate charity care, ... Form 990, CHICAGO, Feb. 25 The ... the process that assists,hospitals in determining whether a ... addresses many of Ohio Attorney General Marc Dann,s,concerns ...
... PORTLAND, Ore., Feb. 25 The Food ... cancer of the colon and,lungs. In off-label use, ... that,s currently used by some doctors to treat ... neck, pancreatic, ovarian,and hepatocellular., Some ophthalmologists are ...
... According to leading weight loss,expert, Dr. Kent Sasse, ... actually cause more weight gain. Insulin, the primary,treatment for ... patients,in part because insulin acts on the fat storage ... these fats., Diabetes mellitus is one of the ...
Other Medicine News:Health News:Omron Healthcare Names New Chief Operating Officer Bob Kondraske 2Health News:Meddius Signs Agreement to Deliver an Integration Platform for Premier's SafetySurveillor(TM) 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 3Health News:TransUnion Addresses Ohio Attorney General's Concerns Surrounding Non-Profit Tax-Exempt Status 2Health News:TransUnion Addresses Ohio Attorney General's Concerns Surrounding Non-Profit Tax-Exempt Status 3Health News:Off-Label Avastin Use for Wet Macular Degeneration 2Health News:Off-Label Avastin Use for Wet Macular Degeneration 3Health News:Cure Diabetes with Weight Loss, Not Drugs, Expert Says 2
(Date:12/16/2009)... N.Y., Dec. 16 BioSpecifics Technologies Corp. ... first in class collagenase-based products, today announced top-line ... clinical trial of XIAFLEX(TM) for the treatment of ... presence of inelastic collagen on the shaft of ... make sexual intercourse difficult or impossible in advanced ...
(Date:12/16/2009)... 16 Vivakor, Inc. (OTC Bulletin ... agreement with Baker Consulting out of Walnut ... Group, Inc. out of South Florida. ... to assist with business development, financing and ... acquisition strategy. Specifically, Baker Consulting is exploring ...
(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... Phase I clinical trial of its lead compound ... in the study. GLYX-13, a glycine site ... NMDA receptor, is initially being developed as a ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4Vivakor Signs Business Development Agreement With Baker Consulting 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Hoarseness predominates in vocal health issues for inner city children 58831 1Designing drugs and their antidotes together improves patient care 58829 1Designing drugs and their antidotes together improves patient care 58829 2Designing drugs and their antidotes together improves patient care 58829 3Global death toll 3A 1 million premature babies every year 58827 1Global death toll 3A 1 million premature babies every year 58827 2Global death toll 3A 1 million premature babies every year 58827 3Global death toll 3A 1 million premature babies every year 58827 4
... - ZIOPHARM Oncology, Inc.,(NASDAQ: ZIOP) announced today that ... the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference on ... the Mandarin Oriental Hotel, New York. Dr. Lewis,will ... update on its,clinical development programs., The presentation will ...
... -- Micromet,Inc. , a biopharmaceutical company focusing on ... inflammatory,and autoimmune diseases, today announced that Dr. Christian ... will,present at the 3rd Annual C.E. Unterberg, Towbin ... 12, 2007 at 10:00am,eastern. , A webcast of ...
Other Medicine Technology:ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference 2Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin,Emerging Growth Conference 2
Histopathology Reference Laboratory provides a full range of histology services, encompassing routine and specialized grossing, processing, embedding, microtomy, routine and special staining and cove...
PhenoPath Laboratories provides screening, diagnostic, and prognostic testing services to hospitals, physician offices, surgery centers, biopharmaceutical companies and research institutions nationwi...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
Medicine Products: